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Abstract
Marginal structural models are causal models designed to adjust for time-dependent confounders in observational
studies with dynamically adjusted treatments. They are robust tools to assess causality in complex longitudinal data.
In this paper, a marginal structural model is proposed with an innovative dose-delay joint-exposure model for Inverse-
Probability-of-Treatment Weighted estimation of the causal effect of alterations to the therapy intensity. The model is
motivated by a precise clinical question concerning the possibility of reducing dosages in a regimen. It is applied to data
from a randomised trial of chemotherapy in osteosarcoma, an aggressive primary bone-tumour. Chemotherapy data are
complex because their longitudinal nature encompasses many clinical details like composition and organisation of multi-
drug regimens, or dynamical therapy adjustments. This manuscript focuses on the clinical dynamical process of adjusting
the therapy according to the patient’s toxicity history, and the causal effect on the outcome of interest of such therapy
modifications. Depending on patients’ toxicity levels, variations to therapy intensity may be achieved by physicians
through the allocation of either a reduction or a delay of the next planned dose. Thus, a negative feedback is present
between exposure to cytotoxic agents and toxicity levels, which acts as time-dependent confounders. The construction
of the model is illustrated highlighting the high complexity and entanglement of chemotherapy data. Built to address
dosage reductions, the model also shows that delays in therapy administration should be avoided. The last aspect makes
sense from the cytological point of view, but it is seldom addressed in the literature.
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1 Introduction
This paper presents a detailed discussion of how to analyse longitudinal chemotherapy data in order to assess the
causal eﬀect on the outcome of interest of weakening the exposure to cytotoxic agents. The outcome of interest
here is Histologic Response (HRe), i.e. the improvement in the appearance of microscopic tissue specimens in a
patient after chemotherapy, see Section 2. There are many a rationale behind such a choice. First, it is motivated
by a precise clinical question (described below); second, it keeps the complexity of the model to a moderate level
and clearly shows both complexity and entanglement of the data; last but not least, HRe is one of the strongest
prognostic factors for survival in bone tumours like osteosarcoma1 or Ewing sarcoma.2
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The analysis of longitudinal chemotherapy data is a complex task because of the presence of a negative
feedback between the allocation of the exposure to chemotherapeutic drugs and the toxicities the latter
provoke. Toxicities, developed by patients through a chemotherapy cycle, aﬀect subsequent exposure by
delaying the next cycle or reducing its dosage. Toxicities are hence time-dependent confounders3: they are at the
same time risk factorsa for HRe and predictors of subsequent exposure.
Marginal structural models (MSMs) were introduced by J. M. Robins in his seminal paper6 as a class of models
for estimating the causal eﬀect of therapy modiﬁcations in presence of time-dependent confounders. MSMs are
often based on Inverse-Probability-of-Treatment Weighted (IPTW) estimators,7,8 which create a pseudo-
population by weighting each subject with the inverse of the probability of observing the allocation of dose
delays/reductions. In this pseudo-population, toxicity history no longer predicts the next exposure, so a crude
analysis estimates the causal eﬀect of exposure modiﬁcations. A similar approach is used, for example, when ﬁtting
a Cox model in the presence of informative censoring,9,10 but in this case the method is known as inverse-
probability-of-censoring weighted (IPCW) estimation.
Alternative to MSMs is the mini-trials approach, described in Klein et al.11 [§7.4]. However, this method works
well only with simple exposure-schemes like starting versus not starting an antiretroviral therapy (and keeping it
indeﬁnitely). The key idea of mini-trials is that at each time period, e.g. every month, a ﬁctitious case-control study
is started, with the control group formed by all patients that have not yet initiated the therapy. When those
patients eventually begin the antiretroviral therapy, they must be artiﬁcially censored from each control group they
are participating to. Since the censoring is clearly informative, IPCW methods are required to compensate the
selection due to the artiﬁcial censoring.
Structural nested models (SNMs)12,13 – and structural nested failure time models (SNFTMs)14–16 in case of
time-to-event data – can also be used in the presence of an exposure-confounder feedback. As the name reveals,
these models are nested and require the speciﬁcation of a quantile–quantile transformation that models the eﬀect
of skipping the kth treatment on the outcome of interest. Fitting a SNM is usually much more complicated than a
MSM and requires g-estimation.17,18 Although there are situations where SNMs overcome limitations in the
applicability of MSMs,19 the latter are enough to address the research question stated below.
This paper presents a MSM designed to mimic a randomised trial where the reduction of the exposure intensity
is no longer confounded by the toxicity. Since the intensity of the exposure can be weakened by allocating dose
reductions and/or cycle delays, an innovative bivariate exposure model is proposed for the computation of the
IPTW estimators. This model is then applied to preoperative data from a large study in resectable osteosarcoma,
EURAMOS-1, where the therapy is a multi-agent regimen called MAP (M: Methotrexate (MTX), A: Doxorubicin
(DOX), P: Cisplatin (CDDP)). Following clinical input, this paper addresses the question ‘‘what is the eﬀect of
reducing MTX by one dose on HRe?’’
Ethical issues make diﬃcult to design clinical trials able to address this research question. Reducing the number of
courses of MTX would greatly improve the patients’ quality of life because of the unpleasant side-eﬀects produced
by this drug at the high dosages administered in osteosarcoma. However, before actually implementing any
reduction in the treatment, thorough assessments of the reduction eﬀects are necessary not to compromise
patients’ prognosis.
MSMs for bivariate exposure-models have been already partially studied in the literature. The earliest example
is discussed in Herna´n et al.,20 where the authors estimate the joint causal eﬀect on survival if the start of anti-
retroviral therapy and prophylaxis for Pneumocystis Carinii Pneumonia (PCP) is delayed. More recently, the joint
eﬀect on mortality of obesity and smoking status was studied in Banack and Kaufman,21 while Howe et al.22
address the risk of HIV acquisition due to joint exposure to alcohol and injection drugs. However, this is the ﬁrst
paper where, to the best of the authors’ knowledge, MSMs are applied to a class of particularly complex data such
as those collected through randomised trials of chemotherapy.
Provided that longitudinal data are available from drug administrations (doses in mg/m2, treatment dates, and
toxicity grades), the model presented here is appropriate to analyse chemotherapy treatments in general. This is
particularly true for the treatment of paediatric cancer, where the exposure-confounder feedback is more pronounced.
2 Complexity of chemotherapy data from randomised trials
Multi-agent regimens are designed to maximise the total cell kill within the range of toxicities tolerated by the
patient.23 They also reduce the chance of developing drug-resistant recurrences, which are typical of single-agent
regimens.24 Thus, cytotoxic agents are usually combined to design protocols, which specify rules for administering
each drug with respect to both dosage and schedule.
2 Statistical Methods in Medical Research 0(0)
Chemotherapy protocols are very diﬃcult to evaluate because of the large number of alternatives one can test.
For example, evidence is in favour of sequential administration of single-agent treatments over multi-drug
combinations in advanced breast cancer.25 In osteosarcoma, the eﬃcacy of combination-chemotherapy is not
debated. Nevertheless, adding one more agent to a two-drug protocol signiﬁcantly improves survival, but the
addition of a fourth drug does not.26 Drug-administration plans, and their organisation in chemotherapy cycles,
are another aspect that must be taken into account. The compression of conventional schedules is thought to
achieve greater eﬃcacy by minimising regrowth of tumour cells between treatment cycles.27
The situation is further complicated by the dynamical adjustment of the treatment on patients’ clinical picture.
Exposure to chemotherapy is likely to produce multi-systemic side eﬀects, e.g. organ toxicity or myelosuppression.
These side eﬀects are a threat to patient’s life and must be controlled by allocating either dose reductions/
discontinuations or delays in the administration of the next course. Toxic side eﬀects are often recorded using
the Common Terminology Criteria for Adverse Events (CTCAE) grades28 from 0 to 5. Many diﬀerent toxicities
are recorded in both randomised and non-randomised controlled trials (usually more than 20), and EURAMOS-1 is
no exception.
Both dose reductions/discontinuations or delays have the eﬀect of reducing the intensity of subsequent
exposure. This is typically measured by the so-called Received Dose Intensityb (RDI)
RDI ¼ 

¼
dose administered
dose planned
time for treatment completion
planned treatment duration
ð1Þ
where  and  are called standardised dose and standardised time, respectively.c On the other hand, physicians are
typically eager to restore nominal exposure levels as soon as possible in order to minimise the chance of tumour
cell regrowth. Thus, a negative exposure-toxicity feedback is always present, it cannot be removed unless ethical
standards are violated, and the eﬃcacy of each protocol can be evaluated through observational studies only.
Another diﬃculty lies in the therapy variations that may be permitted by a ﬂexible protocol. For example, the
EURAMOS-1 protocol allows for the administration of up to 2 extra preoperative doses of MTX. This variation is
present in the protocol to enable physicians to adjust preoperative cumulative doses of MTX, e.g. in case of
surgery delays. Caution is required in this situation to fulﬁll all hypothesis underlying MSMs. For details, see
Section 3.3 below. Also, one has to consider the interconnectedness of drugs: problems with one drug might lead to
delays in the administration of the others.
Finally, one has to deal with the way chemotherapy data were collected. In the EURAMOS-1 dataset, for example,
only the starting date of each cycle is recorded, so that administrations of DOX, CDDP, and MTX from the same
cycle are referred to the same timestamp. In other words, data were thus recorded per-cycle rather than per-
administration, that is, it is not possible to distinguish delays that occurred within or between cycles. In other
situations chemotherapy data might be even recorded just as overall cumulative exposures and severest toxicities,
possibly divided in pre- and post-operative. The way data were collected is a crucial detail and a potential
showstopper for observational studies like the one reported here.
3 Materials and methods
This manuscript analyses preoperative data from EURAMOS-1, a large ongoing study in resectable
osteosarcoma.32–35 The preoperative protocol is a three-drug regimen known as MAP (M: Methotrexate
(MTX), A: Doxorubicin (DOX), P: Cisplatin (CDDP)), structured in two cycles with a nominal duration of
ﬁve weeks each. A dose of DOX (75mg/m2) and one dose of CDDP (120mg/m2) are administered at the
beginning of week 1. Two doses of MTX (12000mg/m2 each) are administered at the beginning of weeks 4 and
5, respectively. Surgery is expected to be performed by week 11, and the resected specimen evaluated immediately
after in order to assess HRe. If less than 10% of the tumour is still viable, then HRe is considered ‘good’, otherwise
‘poor’. Figure 1 shows the organisation of the preoperative treatment and the allocation of therapy modiﬁcations
for a speciﬁc subject.
At clinicians’ discretion, one or two extra courses of MTX could have been administered between the end of
cycle 2 and surgery to adjust the preoperative exposure to MTX. Depending on the HRe, after surgery subjects
were randomised to post-operative treatments having nominal duration of 28 weeks.
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HRe is a strong prognostic factor for both overall and event-free survival.1 Although the main results on
survival in EURAMOS-1 have not yet been published, the association between HRe and survival is suﬃciently
well established that it is taken for granted in the osteosarcoma community.
3.1 Dataset description
The initial dataset included 457 patients enrolled between 2005 and 2011 in the branch of EURAMOS-1 coordinated
by the European Osteosarcoma Intergroup (EOI), these data relate to the dataset described in Whelan et al.35 Only
the starting date of each cycle was recorded in the chemotherapy registration form. Therefore, the cohort for this
analysis was restricted to patients with a registered surgery date because this date was needed to assess delays in
completion of cycle 2. To compensate for the time between end of cycle 2 and surgery, the nominal duration of the
second chemotherapy cycle was extended to six weeks. For this analysis, patients were excluded also in case of
missing HRe and or surgery not performed at the end of cycle 2.d
Filtering patients that met the criteria for this analysis gave 364 patients, of which 58% were males and 42%
were females. Age in the sample ranged from 4 to 40 following a distribution that is in line with the clinical
literature of osteosarcoma. Figure 2 illustrates the patients’ selection through a CONSORT-like diagram.
Among the 93 patients excluded from this analysis, 71 have surely undergone surgery because only one between
HRe and surgery time is missing. The event/censoring time of the remaining 22 patients is in general much larger
than the nominal duration of the preoperative treatment, see Figure 3. In addition, for nearly all of them (20/22),
the completion of preoperative treatment could be assessed from chemotherapy data.
In the chemotherapy registration form of EURAMOS-1, it was possible to record (i) the CTCAE grade of 21
diﬀerent adverse events and (ii) the indication of whether these produced a delay and/or a reduction. Moreover,
the chemotherapy form allowed to grade up to ﬁve additional toxicities in the form of free-text descriptions.
These free-text toxicities contributed more than 500 unique strings describing preoperative adverse events, each of
them associated with the corresponding CTCAE grade and indication of a produced delay/reduction. Both free-
text and protocol toxicities were clinically evaluated and mappede by J.A. – an expert oncologist – onto the
following four categories: Drug Reaction (DR), Infection (II), Altered Laboratory Values (LV), Myelotoxicity
(MT). According to Cole and Herna´n36 [p. 659], this modus operandi is preferable over a more detailed
speciﬁcation of the confounders.
Figure 1. Illustration of the EURAMOS-1 preoperative treatment (a). Example patient (b) experienced a delay of one week in cycle 1
and a discontinuation of the second MTX course and a delay of 18 days in cycle 2.
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As outlined in Section 1, the clinical question motivating this paper targets the possibility of reducing exposure
to MTX. Data of DOX and CDDP was explored ﬁrst to evaluate the administration of these two drugs. Figure 4
plots, for each cycle, the standardised dosef of DOXþCDDP against the standardised dose of MTX. Some
properties of the dataset can be derived from this ﬁgure:
(1) Only a negligible fraction of the subjects reported a reduction in the dosage of DOXþCDDP. This ﬁnding
permits the exclusion of DOXþCDDP from the deﬁnition of the exposure in Section 3.3.
(2) Only course discontinuations occurred in the adjustment of MTX dosage. Indeed, the standardised dose per cycle
of MTX is tightly located around half-integer values, i.e. no partial doses were administered and the number
of MTX courses can be reconstructed from the standardised dose. This ﬁnding is in line with what the
EURAMOS-1 protocol prescribes for MTX about dose modiﬁcations.33 [§9.1.8.2.8].
(3) Collected data are not clear about the eﬀect of toxicities on delays. The chemotherapy registration form
included a ﬁeld named ‘‘did this toxicity cause delay or reduction?’’. However, Figure 4 shows in blue (no
delay/reduction) some subjects with a marked dose reduction of either DOXþCDDP or MTX. To detect
delays, expected cycle durations with the recorded ones were compared.
Figure 5 plots the RDI of MTX against its standardised dose. The solid line satisﬁes the equation RDI ¼ .
Therefore, subjects above this line have a standardised time 4 1 (which means that the end of the cycle was
anticipated), while subjects below this line correspond to 5 1 (which means that they experienced a delay).
Figure 2. CONSORT-like diagram illustrating selection of patients.
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Another two comments can be drawn from this ﬁgure:
(4) The actual duration of cycles presents both anticipations (up to a week) and delays (up to three weeks). This
reﬂects the clinical experience, where variations to the chemotherapy intended-schedule frequently happen
often for practical reasons for scheduling.
(5) Only a negligible fraction of subjects entirely discontinued MTX in cycle 2 (RDI¼ 0). Usually MTX reductions
involved only one of the two courses planned in each cycle.
3.2 Modelling the exposure-toxicity feedback
As mentioned above, the EURAMOS-1 preoperative treatment is structured in two ﬁve-week cycles. Unfortunately,
only the starting date of the cycle was recorded, i.e. the administration date of DOXþCDDP. The two courses of
MTX and the severest CTCAE grades for each toxicity category through a cycle are referred to the starting date of
the cycle itself. In such a situation, it is quite diﬃcult to model the adjustment of the exposure to a single drug on
the past CTCAE history, simply because the inter-cycle causal relationships between exposure and confounders
are entangled in the clinical practice and the limitations of the data design.
As pointed out by Property 1 above, dosage of DOXþCDDP is close to nominal for the large majority of the
subjects and can be thus excluded from the exposure. Moreover, one should keep in mind that clinical evaluations
of toxicity are always performed before starting the administration of every dose. A patient must satisfy a number
of requirements before the administration of any course of MTX. Among these, Mucositis (which falls in the
category MT) not worse than CTCAE grade 1; no liver/urinary/ventricular dysfunctions (all included in LV); an
adequate White Blood Count (WBC) and platelets count (again MT).
The causal structure proposed here for the EURAMOS-1 chemotherapy data is such that the severest CTCAE
grade of each of the four categories DR, II, LV, and MT inﬂuences the exposure in terms of number of MTX doses
and cycle eﬀective duration. Causal relationships between exposure and confounders are usually depicted in a
Direct Acyclic Graph (DAG). Figure 6 shows the one corresponding to the causal structure described above.
Figure 3. Event/censoring time (red and blue, respectively) for the subjects with both HRe and surgery date missing. The dashed line
marks 77 days from registration, i.e. the nominal surgery time; all event/censoring times lie beyond it.
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3.3 Marginal structural model for the histologic response
This section describes the MSM used to measure the causal eﬀect on HRe of reducing by one course the MTX
exposure. First, some notation is introduced:
Outcome. Y is a dichotomous variable describing the outcome (HRe), i.e.
Y ¼ 11f510% viable tumourg ¼
1 if5 10% viable tumour,
0 if  10% viable tumour

ð2Þ
where 11 f g is the indicator function.
According to the deﬁnition of HRe given in Section 3.1, Y¼ 1 is equivalent to a ‘good’ HRe, while Y¼ 0
denotes a ‘poor’ HRe.
Exposure. The exposure administered on cycle k is denoted by the vector
Ak ¼ A1k,A2k
 
 1 52 MTX at cycle kf g, 1 41 week delay at cycle kf g
 
:
ð3Þ
According to equation (3), the exposure on cycle k can take on the following four values:
– (0, 0), at least two courses of MTX were administered during cycle k,g and cycle k was delayed by no more
than a week;
Figure 4. Standardised dose of DOX plus CDDP against standardised dose of MTX. Points lying between the two horizontal (resp.
vertical) dotted lines correspond to an administered dose of DOXþCDDP (resp. MTX) within 5% from the intended dosage. Points
are coloured in red/blue depending on whether, according to the chemotherapy-registration-form dedicated field, at least a toxicity
caused a delay/reduction. On the right part of the lower subfigure, it is possible to notice two groups of patients who received one and
two extra courses of MTX.
Lancia et al. 7
– (0, 1), at least two courses of MTX were administered during cycle k, and cycle k was delayed by at least 8
days;
– (1, 0), only one or zero courses of MTX were administered during cycle k, and the cycle was delayed by no
more than a week;
– (1, 1), only one or zero courses of MTX were administered during cycle k, and cycle k was delayed by at least
eight days.
Figure 5. RDI of MTX against standardised dose of MTX. A cycle lasted less than expected for subjects above the solid line and
more than expected (delay) for subjects below it.
Figure 6. Direct Acyclic Graph (DAG) for the causal relationships between exposure and confounders in EURAMOS-1.
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Confounders. According to the literature on MSMs, where the roman capital letter L is used to indicate a confounder,
the following variables denote the baseline characteristics and the toxicity categories that inﬂuence the allocation of
the kth treatment:
L1k: Drug Reaction (DR) [Toxicity];
L2k: Infection (II) [Toxicity];
L3k: Altered Laboratory Values (LV) [Toxicity];
L4k: Myelotoxicity (MT) [Toxicity];
L5k: Age at registration [Baseline confounder];
L6k: Gender [Baseline confounder].
Figure 7 describes through a stacked bar chart the CTCAE grades measured preoperatively, i.e. in cycle 1 and in
cycle 2.
The subscript k marks the therapy periods (chemotherapy cycles). As such, Lj1 (j ¼ 1, . . . , 6) denotes one of the
confounders that predict A1, i.e. cycle-1 exposure, while L
j
2 denotes one of the confounders that predict A2, i.e.
cycle-2 exposure. Finally, the symbol Lk indicates the vector of the six confounders deﬁned above, i.e.
Lk ¼ L1k,L2k,L3k,L4k,L5k,L6k
 
The past history of a quantity is denoted by placing an overbar on the corresponding symbol, e.g.
Ak  fAjgjk indicates the sequence of exposure values since beginning of therapy until cycle k. In a similar
way, Lk indicates the vector-valued sequence of measured confounders up to (and including) cycle k since the
beginning of therapy.
Counterfactual variables are used in causal modelling to describe a potential outcome, i.e. an outcome that would
be observed had the subject followed, possibly contrary-to-fact, a given treatment.
Counterfactual Outcome. Given the treatment trajectory ð , Þ ¼ ðð1, 1Þ, ð2, 2ÞÞ, let Yð , Þ be the HRe that would
be observed in a subject with exposure history
A11 ¼ 1, A21 ¼ 1,
A21 ¼ 2, A22 ¼ 2, j, j 2 f0, 1g
Figure 7. Stacked bar-chart of the preoperative CTCAE grades for each class of toxicity.
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There are exactly 16 counterfactual outcomes, corresponding to the 16 trajectories ð , Þ that can be realised by
varying 1,2, 1, 2 in {0, 1}.
The model for the histological response is as follows:
Model 1. (MSM logit with bivariate binary-binary exposure)
logit P Yð , Þ ¼ 1  ¼ 0 þ 1cumðAÞ1 þ 2cumðAÞ2
where cumðAÞ is the cumulative-exposure vector
cumðAÞ ¼
X2
k¼1
Ak ¼
X2
k¼1
A1k,
X2
k¼1
A2k
 !
:
The dose component of the cumulative exposure is cumðAÞ1 ¼
P2
k¼1 A
1
k and represents the number of cycles
where MTX was reduced by at least one course. The delay component of the cumulative exposure is
cumðAÞ2 ¼
P2
k¼1A
2
k and represents the number of cycles that were delayed by more than a week. The
interpretation of the model is then as follows: the quantity e1 is the causal Odds Ratio (OR) associated with
reducing the number of courses of MTX in one cycle, while e2 is the causal OR associated with delaying one cycle
by more than a week.
Model 1 does not include any baseline covariates. The reason for such a modelling choice is two-fold: on one
hand, there is no clinical interest in evaluating the causal eﬀect of exposure modiﬁcations within speciﬁc
population strata, see Robins19 [§7.1]; on the other, subjects’ baseline covariates in the EURAMOS-1 dataset other
than age or sex were clinically assessed not to be prognostic factors for HRe.
An interesting model to consider next to Model 1 is the one where extra preoperative MTX is also measured:
Model 2. (MSM logit with bivariate multinomial-binary exposure)
logitP Yð , Þ ¼ 1  ¼ 0 þ 1cumðAÞ1 þ 2cumðAÞ2
where A is an exposure as deﬁned in equation (3) except that the ﬁrst component now measures also excesses of MTX
A1k ¼
1 if 4 2 MTX doses given at cycle k,
0 if 2 MTX doses given at cycle k,
1 if 5 2 MTX doses given at cycle k
8><
>: ð4Þ
The interpretation of Model 2 is similar to that of Model 1.
Under the hypothesis of No Unmeasured Confounder,19,20 both Models 1 and 2 give unbiased estimates of the
causal OR of variations in the number of preoperative MTX courses. Being closer to their daily practice, Model 2
is of greater interest for physicians and should better capture the eﬀect of MTX therapy modiﬁcations. However, it
would not be possible to apply the exposure (4) in a post-operative analysis, while exposure (3) from Model 1
would still work. This is a consequence of the EURAMOS-1 trial-design, which does not allow for extra post-
operative MTX except in the very last cycle (for adjusting the total cumulative dose). For example, since MTX
in excess – observed in cycle 2 – cannot be administered in cycle 3, the hypothesis of Positivity11,37 would be
violated by equation (4).
4 Results
The coeﬃcients 0,1, and 2 in Models 1 and 2 can be correctly estimated via IPTW techniques by a weighted
logistic regression with robust variance estimators, e.g. using R package survey.38 The ith-subject-specﬁc stabilised
weights to be used in such a regression are
swi ¼
Y2
k¼1
P A1i,k, A
2
i,k, jAi,k1
 
P A1i,k, A
2
i,k, jAi,k1,Li,k
  ð5Þ
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Applying the deﬁnition of conditional probability, swi is usually recast
20–22 as follows
swi ¼
Y2
k¼1
P A1i,k jAi,k1
 
P A1i,k jAi,k1,Li,k
 
2
4
3
5 Y2
k¼1
P A2i,k jA1i,k,A2i,k1
 
P A2i,k jA1i,k,A2i,k1,Li,k
 
2
4
3
5: ð6Þ
The swi’s can be estimated by use of equation (6) and existing software like the R package ipw.
39 In case of
Model 1, the stabilised weights can be alternatively estimated from equation (5) using a Bivariate Logistic Odds-
ratio Model (BLOM) – available through the R package VGAM.40 Fitting a joint exposure-model is not exactly in
the original spirit of MSMs, but the computation of the weights with both methods does not show any diﬀerence
anyway. Figure 8 shows a plot of the weights (equation (6)) used to ﬁt Model 2. The left boxplot corresponds to
the product of the factors for k¼ 1 only, while the right boxplot shows the ﬁnal weights.
Tables 1 and 2 show estimates and Conﬁdence Intervals (CIs) of 0,1, and 2 for Models 1 and 2, respectively.
In both models, decreasing MTX in one cycle has a positive eﬀect on HRe, while delaying one cycle by more than a
week has a negative eﬀect. With respect to Model 1, the negative eﬀect of delaying a cycle is in Model 2 more
pronounced (OR 0.564 vs. 0.636) and becomes (barely) signiﬁcant (p-value 0.045 vs. 0.103). Since a negative eﬀect
of delays is in accordance with the cytological intuition,h this suggests that Model 2 might better capture the
routine clinical practice. The formulation of Models 1 and 2 diﬀers only slightly, as the range of cumðAÞ1 is {0, 1,
2} while that of cumðAÞ1 is just f1, 0, 1, 2g. Nevertheless, the eﬀect of cumulative delay is statistically signiﬁcant
in 2 only. This is attributable to the diﬀerent way in which equation (6) weights patients with an excess of MTX.
−2
−1
0
1
2
1 2
cycle
lo
g(i
ptw
)
Figure 8. Diagnostic boxplot of subject-specific weights computed via equation (6). The scale on the y-axis is logarithmic. The left
boxplot corresponds to the terms with k¼ 1 only, while the right one corresponds to the full product.
Table 1. Model 1: Odds ratio (OR) and 95% confidence interval (CI).
OR 95% CI
(Intercept) 1.300 [0.971, 1.739]
cumðAÞ1 1.295 [0.697, 2.404]
cumðAÞ2 0.636 [0.370, 1.094]
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Although there is a substantial balance between Poor and Good HRe (10 vs. 12) in the original group of patients
that received extra MTX, in the pseudo-population this ratio is nearly 3:1 (55.21 vs. 20.13). The observed increase
in the OR of the cumulative reduction from Models 1 to 2 is consistent with this remark. The gain of power is a
natural consequence of the lower panel of Figure 5.
Based on the results reported, there is no evidence to support the hypothesis that a reduction in the number of
courses of MTX might improve the HRe whilst accounting for patients that could have had an increased number
of cycles for unrecorded reasons. However, in a clinical scenario where an operative choice need to be taken
between
– giving two courses of MTX but delaying the cycle because of high toxicity,
– skipping one course of MTX and not delaying the end of the cycle, the ﬁndings of Models 1 and 2 suggest that
the latter decision should probably be taken.
5 Conclusions
This paper discussed the application of MSMs, a well-established methodology in causal inference, to a novel class
of longitudinal data. These are pre-randomisation data collected in a randomised clinical trial of chemotherapy.
This research was motivated by a sharp yet delicate clinical question on the eﬀect of reducing the exposure to one
of the chemotherapy agents administered during the EURAMOS-1 trial.
The outcome addressed by the paper, HRe, is acknowledged as one of the strongest prognostic factors for
survival in osteosarcoma.1 Moreover, addressing the HRe allowed the use of data from 95 non-randomised
subjects. These are patients that were not admitted to or refused to enroll on post-operative treatment.
Concerning the possibility of reducing the number of courses of MTX tout-court, ORs listed in Tables 1 and 2
are not statistically signiﬁcant, so no compelling conclusion can be provided. It would be interesting to repeat the
analysis with a separate, larger dataset, where hopefully a stronger fraction of the subjects have a reduced number
of courses of MTX and/or delayed cycles. Indeed, Figure 5 shows a strong unbalance among the trajectories ( , ),
with the majority of subjects having no reductions and no delays (larger than a week). For this manuscript, it was
only possible to get access to the EOI-collected data from the EURAMOS-1 trial.
A major achievement of this work is having shown the potentially detrimental eﬀect of chemotherapy
delays, an aspect of treatment data seldom addressed in the literature. If conﬁrmed by other studies, especially
on survival outcomes, the negative eﬀect of chemotherapy delays could call for a modiﬁcation of current clinical
practice.
As a ﬁnal remark, a validation study using another independent dataset is highly recommended to increase the
overall impact of this study. Veriﬁcation of the negative eﬀect of delaying a therapy cycle in osteosarcoma could be
sought in three past European Organisation for Research and Treatment of Cancer (EORTC) studies, namely,
trials 80831, 80861, and 80931 (EOI trials BO02, BO03, and BO06, respectively). Subjects randomised to the
control arm of these studies are administered identical doses of DOXþCDDP. About the eﬀect of MTX, more
insight could be possibly achieved by analysing data from the case arm of EORTC randomised trial 80831 (EOI
trial BO02), where the preoperative cumulative dosage of DOX and CDDP are substantially similar to EURAMOS-1
but the dosages of MTX are in ratio 1:3. This is work in progress.
Declaration of conflicting interests
The author(s) declared no potential conﬂicts of interest with respect to the research, authorship, and/or publication of this
article.
Table 2. Model 2: OR and 95% CI.
OR 95% CI
(Intercept) 1.289 [0.958, 1.735]
cumðAÞ1 1.460 [0.802, 2.656]
cumðAÞ2 0.564 [0.323, 0.986]
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Notes
a. There is clinical evidence of toxicity being associated with HRe in breast cancer.4 The very same association is not well-
established in osteosarcoma, although there is evidence that toxicity are predictors for survival.5
b. Received Dose Intensity (RDI) is historically considered a major prognostic factor27,29 although recent results contrast this
belief for osteosarcoma at least.1,30,31.
c. In general   1 and   1 as a consequence of reductions, delays, and discontinuation. Thus, RDI  1 with the following
interpretation: the smaller the value of RDI, the more evident the delays and/or the reductions occurred throughout the
treatment.
d. Reasons for not performing surgery at the end of cycle 2 include progressing disease and tumour localised in bones difficult
to operate, e.g. pelvis or mandible.
e. Keeping the highest CTCAE grade.
f. Analogously to the quantity  appearing in (1), the standardised dose is computed here as the ratio dose received over dose
planned in each cycle (averaged over the number of drugs).
g. Recall that EURAMOS-1 allows for up to 2 extra pre-operative courses of MTX.
h. Roughly speaking, if a delay is introduced in the therapy plan, the chance of tumour regrowth increases.
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